AI summary · may contain errors
Eplontersen (45 mg every 4 weeks) did not reduce the 140-week risk of a composite of cardiovascular death and recurrent cardiovascular events in patients with ATTR-CM (rate ratio 0.89; P=0.28).
- 19 cites
Moving in Blood and New England Journal of Medicine.
Rebuilt
AI summary · may contain errors
Eplontersen (45 mg every 4 weeks) did not reduce the 140-week risk of a composite of cardiovascular death and recurrent cardiovascular events in patients with ATTR-CM (rate ratio 0.89; P=0.28).
AI summary · may contain errors
In newly diagnosed light-chain (AL) amyloidosis, adding subcutaneous daratumumab to VCd (D-VCd) improved overall survival with a hazard ratio of 0.62 after 61.4 months’ follow-up.
Newest first · last 60 days
AI summary · may contain errors
Soft tissue-to-bone ratio above 0.5 on routine whole-body bone scintigraphy in 8,769 Austrian patients without cardiac uptake is linked to higher all-cause mortality (aHR 1.73).
AI summary · may contain errors
Protein misfolding diseases are linked to cardiovascular dysfunction, including microvascular injury and thrombosis, driven by proteostasis failure, oligomer toxicity, amyloid deposition, and inflammation.
AI summary · may contain errors
A hypothesis-generating model of AA amyloidosis predicts a threshold in kidney aggregation dynamics where autocatalytic oligomer production balances oligomer loss, producing a transcritical bifurcation.
AI summary · may contain errors
Higher CD68+ macrophage infiltration in diagnostic kidney biopsies from 708 patients with immunoglobulin light-chain amyloidosis predicts worse kidney survival, with 5-year RRT rising from 14% to 52% across scores 0–3.
AI summary · may contain errors
A 57-year-old man with periorbital purpura, fatigue, and biventricular hypertrophy on echocardiography was diagnosed with systemic amyloidosis.
AI summary · may contain errors
In newly diagnosed transthyretin amyloid cardiomyopathy, quantitative tricuspid regurgitation thresholds (VCW, EROA, RegVol) stratify mortality and HF hospitalization, with extreme risk at VCW ≥8 mm.
AI summary · may contain errors
In renal AL amyloidosis, macrophage infiltration on kidney biopsy predicts progression to renal replacement therapy despite sustained deep hematologic response, highlighting a paradoxical role.
AI summary · may contain errors
In the CARDIO-TTRansform phase 3 trial for transthyretin amyloid cardiomyopathy, baseline TTR stabilizer use strongly modified eplontersen’s effect (P interaction=0.017).
AI summary · may contain errors
Basal IAPP monomer secretion rate and spontaneous oligomer dissociation rate dominate long-term accumulated cytotoxicity in a beta-cell/islet aggregation model, with sensitivities near +1 and −1.
AI summary · may contain errors
Immediate 99mTc-HDP SPECT/CT showed 100% diagnostic concordance with 1-hour imaging for suspected transthyretin amyloid cardiomyopathy, with kappa = 1.000.
AI summary · may contain errors
Daratumumab monotherapy in newly diagnosed Mayo2004/European cardiac stage IIIB AL amyloidosis achieved a 65% 6-month overall survival rate and median OS of 10.4 months.
AI summary · may contain errors
Population-based MGUS screening in Iceland increased smoldering multiple myeloma detection 27-fold (8.6% vs 0.3%; hazard ratio 27.46) after 4.5 years.
AI summary · may contain errors
Plasma neurofilament light polypeptide (NfL) is elevated in Danish EPIC participants who later develop amyotrophic lateral sclerosis (ALS) up to 14.6 years before diagnosis, with odds rising to 3.8 per SD.
AI summary · may contain errors
Worse left atrial reservoir and contractile strain in HELIOS-B patients with transthyretin amyloidosis with cardiomyopathy predicts higher all-cause mortality and recurrent cardiovascular events.
AI summary · may contain errors
Vutrisiran treatment in UK HELIOS-B participants with transthyretin amyloid cardiomyopathy is linked to favorable CMR changes, including ECV reduction of -6.56% (P < .001).
AI summary · may contain errors
A mass-spectrometry workflow assembled eight urinary N-glycosylated monoclonal light-chain sequences in AL amyloidosis, with deglycosylation-enabled intact-mass agreement confirming full-length accuracy.
AI summary · may contain errors
In six relapsed/refractory AL amyloidosis patients, BCMA-CD19 dual-targeted CAR-T therapy produced 100% hematologic and renal complete responses after a median 640-day follow-up.
AI summary · may contain errors
Amyloid-targeting therapies in Alzheimer disease patients with suspected copathologies require individualized clinical decisions because evidence is incomplete and prospective data are needed.
AI summary · may contain errors
A random survival forest time-to-event model for transthyretin cardiac amyloidosis (ATTR-CM) predicts mortality and heart-failure hospitalization with Harrell C-indices of 0.74–0.77 across held-out cohorts.
AI summary · may contain errors
In 548 participants with transthyretin amyloidosis with cardiomyopathy, abnormal RV free wall strain (RVFWS ≤20%) was present in 85% and predicted mortality and recurrent CV events.
AI summary · may contain errors
Vutrisiran’s effect on all-cause mortality and recurrent cardiovascular events in HELIOS-B ATTR-CM is directionally consistent regardless of baseline tafamidis use, with rate ratios 0.79 vs 0.67.
Journals this month
Topics moving, week to 17 Nov 2026
By field